Nigerian Doctor Bags "Brain-Tumor Research" Award In US
Chibawanye Ene, a Nigerian US-Based Doctor wins Brain-Tumor Research Award in United States. He received the award at the 2019 American Association of Neurological Surgeons (AANS) annual scientific meeting which held from April 13 to April 17 in San Diego, US.
Did you know? You can comment on this post! Just scroll down
Ene, 37, hails from Akpugo in Nkanu west local government area of Enugu state. He won the award with his research work titled: “Anti-PD-L1 Immunotherapy Enhances Radiation-induced Abscopal Response in Glioblastoma”.
Glioblastoma is an aggressive form of cancer that can occur in the brain or spinal cord with symptoms ranging from headaches to personality changes, nausea, and incontinence.
Immunotherapy is a type of cancer treatment that helps immune system fight cancer, although it has been largely unsuccessful in the treatment of Glioblastoma.
According to the journal, the molecular structure of the tumor found in that form of cancer only allows few of the cancerous cells to be eliminated during treatment.
The new findings in Ene’s research have shown promise for better treatment options, revealing that “radiation combined with Anti PD L1 therapy induces an immunological response to unirradiated glioblastoma”.
“The researchers are currently optimizing other treatment combinations that could also be readily assessed in phase I human clinical trials,” the journal said.
Article Posted 5 Years ago. You can post your own articles and it will be published for free.
No Registration is required! But we review before publishing! Click here to get started
One Favour Please! Subscribe To Our YouTube Channel!
468k
Cook Amazing Nigerian Dishes, Follow Adorable Kitchen YouTube Channel!
1.1m
Like us on Facebook, Follow on Twitter
React and Comment
Click Here To Hide More Posts Like This
Watch and Download Free Mobile Movies, Read entertainment news and reports, Download music and Upload your own For FREE.
Submit Your Content to be published for you FREE! We thrive on user-submitted content!
But we moderate!